June 2, 2021 07:47 AM EDT

After taking a look at new data, regulators put J&J's BCMA/CD3 bispecific on a 'breakthrough' track

After offering a peek at the updated data it’s bringing to ASCO next week, J&J is moving into the fast lane …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Af­ter tak­ing a look at new da­ta, reg­u­la­tors put J&J's BC­MA/CD3 bis­pe­cif­ic on a 'break­through' track